Top

Published in:

Open Access 01-02-2019 | Article

Skin autofluorescence predicts incident type 2 diabetes, cardiovascular disease and mortality in the general population

Authors: Robert P. van Waateringe, Bernardina T. Fokkens, Sandra N. Slagter, Melanie M. van der Klauw, Jana V. van Vliet-Ostaptchouk, Reindert Graaff, Andrew D. Paterson, Andries J. Smit, Helen L. Lutgers, Bruce H. R. Wolffenbuttel

Published in: Diabetologia | Issue 2/2019

Abstract

Aims/hypothesis

Earlier studies have shown that skin autofluorescence measured with an AGE reader estimates the accumulation of AGEs in the skin, which increases with ageing and is associated with the metabolic syndrome and type 2 diabetes. In the present study, we examined whether the measurement of skin autofluorescence can predict 4 year risk of incident type 2 diabetes, cardiovascular disease (CVD) and mortality in the general population.

Methods

For this prospective analysis, we included 72,880 participants of the Dutch Lifelines Cohort Study, who underwent baseline investigations between 2007 and 2013, had validated baseline skin autofluorescence values available and were not known to have diabetes or CVD. Individuals were diagnosed with incident type 2 diabetes by self-report or by a fasting blood glucose ≥7.0 mmol/l or HbA_1c ≥48 mmol/mol (≥6.5%) at follow-up. Participants were diagnosed as having incident CVD (myocardial infarction, coronary interventions, cerebrovascular accident, transient ischaemic attack, intermittent claudication or vascular surgery) by self-report. Mortality was ascertained using the Municipal Personal Records Database.

Results

After a median follow-up of 4 years (range 0.5–10 years), 1056 participants (1.4%) had developed type 2 diabetes, 1258 individuals (1.7%) were diagnosed with CVD, while 928 (1.3%) had died. Baseline skin autofluorescence was elevated in participants with incident type 2 diabetes and/or CVD and in those who had died (all p < 0.001), compared with individuals who survived and remained free of the two diseases. Skin autofluorescence predicted the development of type 2 diabetes, CVD and mortality, independent of several traditional risk factors, such as the metabolic syndrome, glucose and HbA_1c.

Conclusions/interpretation

The non-invasive skin autofluorescence measurement is of clinical value for screening for future risk of type 2 diabetes, CVD and mortality, independent of glycaemic measures and the metabolic syndrome.

Available only for authorised users

Wolffenbuttel BHR, Van Haeften TW (1995) Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM). Drugs 50(2):263–288. https://doi.org/10.2165/00003495-199550020-00006 CrossRefPubMed

Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54(6):1615–1625. https://doi.org/10.2337/diabetes.54.6.1615 CrossRefPubMed

Ford ES (2011) Trends in the risk for coronary heart disease among adults with diagnosed diabetes in the U.S.: findings from the National Health and Nutrition Examination Survey, 1999-2008. Diabetes Care 34(6):1337–1343. https://doi.org/10.2337/dc10-2251 CrossRefPubMedPubMedCentral

Lindstrom J, Tuomilehto J (2003) The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 26(3):725–731. https://doi.org/10.2337/diacare.26.3.725 CrossRefPubMed

Conroy RM, Pyorala K, Fitzgerald AP et al (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24(11):987–1003. https://doi.org/10.1016/S0195-668X(03)00114-3 CrossRefPubMed

D’Agostino RB Sr, Vasan RS, Pencina MJ et al (2008) General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117(6):743–753. https://doi.org/10.1161/CIRCULATIONAHA.107.699579 CrossRefPubMed

Noble D, Mathur R, Dent T, Meads C, Greenhalgh T (2011) Risk models and scores for type 2 diabetes: systematic review. BMJ 343:d7163. https://doi.org/10.1136/bmj.d7163 CrossRefPubMedPubMedCentral

Monnier VM (1990) Nonenzymatic glycosylation, the Maillard reaction and the aging process. J Gerontol 45(4):B105–B111. https://doi.org/10.1093/geronj/45.4.B105 CrossRefPubMed

Brownlee M (1995) Advanced protein glycosylation in diabetes and aging. Annu Rev Med 46(1):223–234. https://doi.org/10.1146/annurev.med.46.1.223 CrossRefPubMed

10.

Baynes JW, Thorpe SR (2000) Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 28(12):1708–1716. https://doi.org/10.1016/S0891-5849(00)00228-8 CrossRefPubMed

11.

Aronson D (2003) Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens 21(1):3–12. https://doi.org/10.1097/00004872-200301000-00002 CrossRefPubMed

12.

Liu CY, Huang QF, Cheng YB et al (2017) A comparative study on skin and plasma advanced glycation end products and their associations with arterial stiffness. Pulse (Basel) 4(4):208–218. https://doi.org/10.1159/000453581 CrossRef

13.

Basta G, Schmidt AM, De Caterina R (2004) Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 63(4):582–592. https://doi.org/10.1016/j.cardiores.2004.05.001 CrossRefPubMed

14.

Isermann B, Bierhaus A, Humpert PM et al (2004) AGE-RAGE: a hypothesis or a mechanism? Herz 29(5):504–509 [article in German]. https://doi.org/10.1007/s00059-004-2611-3 CrossRefPubMed

15.

Lin N, Zhang H, Su Q (2012) Advanced glycation end-products induce injury to pancreatic beta cells through oxidative stress. Diabetes Metab 38(3):250–257. https://doi.org/10.1016/j.diabet.2012.01.003 CrossRefPubMed

16.

Vlassara H, Uribarri J (2014) Advanced glycation end products (AGE) and diabetes: cause, effect, or both? Curr Diab Rep 14(1):453. https://doi.org/10.1007/s11892-013-0453-1 CrossRefPubMedPubMedCentral

17.

Meerwaldt R, Graaff R, Oomen PHN et al (2004) Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 47(7):1324–1330. https://doi.org/10.1007/s00125-004-1451-2 CrossRefPubMed

18.

Meerwaldt R, Links T, Graaff R et al (2005) Simple noninvasive measurement of skin autofluorescence. Ann N Y Acad Sci 1043(1):290–298. https://doi.org/10.1196/annals.1333.036 CrossRefPubMed

19.

Lutgers HL, Graaff R, Links TP et al (2006) Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care 29(12):2654–2659. https://doi.org/10.2337/dc05-2173 CrossRefPubMed

20.

Koetsier M, Lutgers HL, de Jonge C, Links TP, Smit AJ, Graaff R (2010) Reference values of skin autofluorescence. Diabetes Technol Ther 12(5):399–403. https://doi.org/10.1089/dia.2009.0113 CrossRefPubMed

21.

Van Waateringe RP, Slagter SN, van Beek AP et al (2017) Skin autofluorescence, a non-invasive biomarker for advanced glycation end products, is associated with the metabolic syndrome and its individual components. Diabetol Metab Syndr 9(1):42. https://doi.org/10.1186/s13098-017-0241-1 CrossRefPubMedPubMedCentral

22.

Gerrits EG, Lutgers HL, Kleefstra N et al (2008) Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care 31(3):517–521. https://doi.org/10.2337/dc07-1755 CrossRefPubMed

23.

Noordzij MJ, Mulder DJ, Oomen PH et al (2012) Skin autofluorescence and risk of micro- and macrovascular complications in patients with type 2 diabetes mellitus-a multi-centre study. Diabet Med 29(12):1556–1561. https://doi.org/10.1111/dme.12005 CrossRefPubMed

24.

Tanaka K, Tani Y, Asai J et al (2012) Skin autofluorescence is associated with severity of vascular complications in Japanese patients with type 2 diabetes. Diabet Med 29(4):492–500. https://doi.org/10.1111/j.1464-5491.2011.03448.x CrossRefPubMed

25.

De Vos LC, Mulder DJ, Smit AJ et al (2014) Skin autofluorescence is associated with 5-year mortality and cardiovascular events in patients with peripheral artery disease. Arterioscler Thromb Vasc Biol 34(4):933–938. https://doi.org/10.1161/ATVBAHA.113.302731 CrossRefPubMed

26.

De Vos LC, Boersema J, Mulder DJ, Smit AJ, Zeebregts CJ, Lefrandt JD (2015) Skin autofluorescence as a measure of advanced glycation end products deposition predicts 5-year amputation in patients with peripheral artery disease. Arterioscler Thromb Vasc Biol 35(6):1532–1537. https://doi.org/10.1161/ATVBAHA.115.305407 CrossRefPubMed

27.

Stolk RP, Rosmalen JG, Postma DS et al (2008) Universal risk factors for multifactorial diseases: LifeLines: a three-generation population-based study. Eur J Epidemiol 23(1):67–74. https://doi.org/10.1007/s10654-007-9204-4 CrossRefPubMed

28.

Scholtens S, Smidt N, Swertz MA et al (2015) Cohort profile: LifeLines, a three-generation cohort study and biobank. Int J Epidemiol 44(4):1172–1180. https://doi.org/10.1093/ije/dyu229 CrossRefPubMed

29.

Van Waateringe RP, Slagter SN, van der Klauw MM et al (2016) Lifestyle and clinical determinants of skin autofluorescence in a population-based cohort study. Eur J Clin Investig 46(5):481–490. https://doi.org/10.1111/eci.12627 CrossRef

30.

Koetsier M, Nur E, Chunmao H et al (2010) Skin color independent assessment of aging using skin autofluorescence. Opt Express 18(14):14416–14429. https://doi.org/10.1364/OE.18.014416 CrossRefPubMed

31.

Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612. https://doi.org/10.7326/0003-4819-150-9-200905050-00006 CrossRefPubMedPubMedCentral

32.

Alberti KG, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120(16):1640–1645. https://doi.org/10.1161/CIRCULATIONAHA.109.192644 CrossRefPubMed

33.

Dyer DG, Dunn JA, Thorpe SR et al (1993) Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 91(6):2463–2469. https://doi.org/10.1172/JCI116481 CrossRefPubMedPubMedCentral

34.

Maynard JD, Rohrscheib M, Way JF, Nguyen CM, Ediger MN (2007) Noninvasive type 2 diabetes screening: superior sensitivity to fasting plasma glucose and A1C. Diabetes Care 30(5):1120–1124. https://doi.org/10.2337/dc06-2377 CrossRefPubMed

35.

Smit AJ, Smit JM, Botterblom GJ, Mulder DJ (2013) Skin autofluorescence based decision tree in detection of impaired glucose tolerance and diabetes. PLoS One 8(6):e65592. https://doi.org/10.1371/journal.pone.0065592 CrossRefPubMedPubMedCentral

36.

Fokkens BT, van Waateringe RP, Mulder DJ, Wolffenbuttel BHR, Smit AJ (2018) Skin autofluorescence improves the Finnish Diabetes Risk Score in the detection of diabetes in a large population-based cohort: the LifeLines Cohort Study. Diabetes Metab 44(5):424–430. https://doi.org/10.1016/j.diabet.2017.09.002 CrossRefPubMed

37.

Kuk JL, Ardern CI (2010) Age and sex differences in the clustering of metabolic syndrome factors: association with mortality risk. Diabetes Care 33(11):2457–2461. https://doi.org/10.2337/dc10-0942 CrossRefPubMedPubMedCentral

38.

Klein BE, Klein R, Lee KE (2002) Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care 25(10):1790–1794. https://doi.org/10.2337/diacare.25.10.1790 CrossRefPubMed

39.

Mons U, Muezzinler A, Gellert C et al (2015) Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults: meta-analysis of individual participant data from prospective cohort studies of the CHANCES consortium. BMJ 350:h1551. https://doi.org/10.1136/bmj.h1551 CrossRefPubMedPubMedCentral

40.

Teo KK, Ounpuu S, Hawken S et al (2006) Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet 368(9536):647–658. https://doi.org/10.1016/S0140-6736(06)69249-0 CrossRefPubMed

41.

Cerami C, Founds H, Nicholl I et al (1997) Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci U S A 94(25):13915–13920. https://doi.org/10.1073/pnas.94.25.13915 CrossRefPubMedPubMedCentral

42.

Nicholl ID, Stitt AW, Moore JE, Ritchie AJ, Archer DB, Bucala R (1998) Increased levels of advanced glycation endproducts in the lenses and blood vessels of cigarette smokers. Mol Med 4(9):594–601. https://doi.org/10.1007/BF03401759 CrossRefPubMedPubMedCentral

43.

Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EF (2007) Systemic effects of smoking. Chest 131(5):1557–1566. https://doi.org/10.1378/chest.06-2179 CrossRefPubMed

44.

Van Waateringe RP, Mook-Kanamori MJ, Slagter SN et al (2017) The association between various smoking behaviors, cotinine biomarkers and skin autofluorescence, a marker for advanced glycation end product accumulation. PLoS One 12(6):e0179330. https://doi.org/10.1371/journal.pone.0179330 CrossRefPubMedPubMedCentral

45.

Meerwaldt R, Lutgers HL, Links TP et al (2007) Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 30(1):107–112. https://doi.org/10.2337/dc06-1391 CrossRefPubMed

46.

Meerwaldt R, Hartog JW, Graaff R et al (2005) Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 16(12):3687–3693. https://doi.org/10.1681/ASN.2005020144 CrossRefPubMed

47.

Fraser SD, Roderick PJ, McIntyre NJ et al (2014) Skin autofluorescence and all-cause mortality in stage 3 CKD. Clin J Am Soc Nephrol 9(8):1361–1368. https://doi.org/10.2215/CJN.09510913 CrossRefPubMedPubMedCentral

48.

Macsai E, Benke A, Kiss I (2015) Skin autofluorescence and mortality in patients on peritoneal dialysis. Medicine (Baltimore) 94(45):e1933. https://doi.org/10.1097/MD.0000000000001933 CrossRef

Title: Skin autofluorescence predicts incident type 2 diabetes, cardiovascular disease and mortality in the general population
Authors: Robert P. van Waateringe
Bernardina T. Fokkens
Sandra N. Slagter
Melanie M. van der Klauw
Jana V. van Vliet-Ostaptchouk
Reindert Graaff
Andrew D. Paterson
Andries J. Smit
Helen L. Lutgers
Bruce H. R. Wolffenbuttel
Publication date: 01-02-2019
Publisher: Springer Berlin Heidelberg
Published in: Diabetologia / Issue 2/2019
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-018-4769-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Please log in to get access to this content

Other articles of this Issue 2/2019

A call for improved reporting of human islet characteristics in research articles

Increased NEFA levels reduce blood Mg2+ in hypertriacylglycerolaemic states via direct binding of NEFA to Mg2+

Up front

Use of human islets to understand islet biology and diabetes: progress, challenges and suggestions

A variant of the glucose transporter gene SLC2A2 modifies the glycaemic response to metformin therapy in recently diagnosed type 2 diabetes

Gestational diabetes in young women predicts future risk of serious liver disease

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials